

Sonja Zweegman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4794637/publications.pdf>

Version: 2024-02-01

231
papers

12,871
citations

50244

46
h-index

26591

107
g-index

232
all docs

232
docs citations

232
times ranked

11284
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology, The</i> , 2014, 15, e538-e548.	5.1	3,343
2	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	0.8	735
3	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	6.3	665
4	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
5	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2017, 18, e206-e217.	5.1	394
6	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
7	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. <i>Blood</i> , 2016, 128, 959-970.	0.6	286
8	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2014, 15, 333-342.	5.1	256
9	Autologous haematopoietic stem-cell transplantation versus bortezomib+melfalan+prednisone, with or without bortezomib+lenalidomide+dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology, the</i> , 2020, 7, e456-e468.	2.2	244
10	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology, the</i> , 2017, 4, e317-e324.	2.2	243
11	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. <i>Molecular Therapy</i> , 2017, 25, 1946-1958.	3.7	197
12	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	1.7	193
13	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	6.3	187
14	Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2014, 9, e107587.	1.1	164
15	Molecular basis of resistance to proteasome inhibitors in hematological malignancies. <i>Drug Resistance Updates</i> , 2015, 18, 18-35.	6.5	153
16	Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study. <i>Blood</i> , 2008, 112, 461-461.	0.6	153
17	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021, 22, e105-e118.	5.1	136
18	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. <i>Clinical Cancer Research</i> , 2017, 23, 7498-7511.	3.2	134

#	ARTICLE	IF	CITATIONS
19	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , 2014, 99, 984-996.	1.7	124
20	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	1.7	118
21	Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. <i>Cancer & Metabolism</i> , 2017, 5, 7.	2.4	115
22	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
23	Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4014-4025.	3.2	110
24	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
25	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. <i>Drugs</i> , 2018, 78, 19-37.	4.9	108
26	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. <i>Blood</i> , 2016, 127, 1109-1116.	0.6	102
27	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e119-e130.	5.1	92
28	CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, e100-e103.	1.7	90
29	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
30	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
31	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
32	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
33	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
34	Elderly patients with multiple myeloma: towards a frailty approach?. <i>Current Opinion in Oncology</i> , 2017, 29, 315-321.	1.1	77
35	Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 17.	2.8	75
36	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68

#	ARTICLE	IF	CITATIONS
37	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	1.2	67
38	Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease. <i>Clinical Cancer Research</i> , 2014, 20, 5888-5897.	3.2	64
39	CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide. <i>Haematologica</i> , 2022, 107, 437-445.	1.7	63
40	Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 449-456.	0.6	60
41	Preclinical activity and determinants of response of the GPRC5D \times CD3 bispecific antibody talquetamab in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2196-2215.	2.5	56
42	Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients. <i>Haematologica</i> , 2020, 105, e302-e306.	1.7	53
43	Preclinical Activity of JNJ-7957, a Novel BCMA \times CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. <i>Clinical Cancer Research</i> , 2020, 26, 2203-2215.	3.2	53
44	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8000-8000.	0.8	52
45	Age and aging in blood disorders: multiple myeloma. <i>Haematologica</i> , 2014, 99, 1133-1137.	1.7	50
46	Performance of ⁸⁹ Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828.	1.1	50
47	Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2016, 128, 2297-2306.	0.6	49
48	Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. <i>Science Translational Medicine</i> , 2021, 13, eabh1962.	5.8	49
49	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	1.7	46
50	Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. <i>Blood Cancer Journal</i> , 2021, 11, 40.	2.8	46
51	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
52	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	1.2	45
53	Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. <i>Haematologica</i> , 2018, 103, e368-e371.	1.7	43
54	Ixazomib for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1949-1968.	0.9	42

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. <i>Blood</i> , 2019, 134, 692-692.	0.6	42
56	Antileukemic Activity and Mechanism of Drug Resistance to the Marine <i>Salinispora tropica</i> Proteasome Inhibitor Salinosporamide A (Marizomib). <i>Molecular Pharmacology</i> , 2014, 86, 12-19.	1.0	39
57	Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. <i>Leukemia</i> , 2022, 36, 1066-1077.	3.3	39
58	⁸⁹ Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832.	2.8	38
59	Targeted Therapy With Immunoconjugates for Multiple Myeloma. <i>Frontiers in Immunology</i> , 2020, 11, 1155.	2.2	38
60	Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924. <i>Biochemical Pharmacology</i> , 2014, 89, 43-51.	2.0	36
61	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	1.8	36
62	Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. <i>Blood Cancer Journal</i> , 2021, 11, 38.	2.8	36
63	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	4.9	34
64	Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 651-660.	3.3	33
65	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
66	CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 197-206.	1.3	30
67	(Immuno)proteasomes as therapeutic target in acute leukemia. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 599-615.	2.7	29
68	Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 673-673.	0.6	29
69	A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 121, 74-89.	2.0	28
70	Resistance Mechanisms towards CD38-Directed Antibody Therapy in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 1195.	1.0	28
71	Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study. <i>Blood</i> , 2008, 112, 649-649.	0.6	28
72	Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial. <i>Blood</i> , 2015, 126, 27-27.	0.6	28

#	ARTICLE	IF	CITATIONS
73	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. <i>Haematologica</i> , 2019, 104, 2274-2282.	1.7	27
74	Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis. <i>Clinical Cancer Research</i> , 2021, 27, 3793-3803.	3.2	27
75	Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. <i>Blood Reviews</i> , 2021, 49, 100808.	2.8	27
76	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 764-768.	0.5	26
77	Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial). <i>Blood</i> , 2016, 128, 242-242.	0.6	26
78	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
79	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2758-2767.	0.8	25
80	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
81	¹⁸ F-FDG or ¹⁸ F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 216-221.	2.8	24
82	Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies. <i>Cancers</i> , 2020, 12, 3713.	1.7	23
83	T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 4076-4081.	0.8	23
84	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 82.	6.9	22
85	RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. <i>Blood</i> , 2018, 131, 2485-2489.	0.6	22
86	Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. <i>Leukemia</i> , 2020, 34, 1964-1966.	3.3	22
87	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
88	Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5128-5139.	2.5	22
89	A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response. <i>Nature Cancer</i> , 2020, 1, 1054-1065.	5.7	21
90	Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e874-e883.	2.2	20

#	ARTICLE	IF	CITATIONS
91	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. <i>Haematologica</i> , 2020, 105, 2879-2882.	1.7	20
92	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021, 5, e562.	1.2	20
93	Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e9-e11.	0.2	19
94	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. <i>Haematologica</i> , 2020, 105, 1650-1659.	1.7	19
95	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2018, 132, 596-596.	0.6	19
96	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. <i>Haematologica</i> , 2015, 100, 677-682.	1.7	18
97	Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients. <i>Haematologica</i> , 2015, 100, e90-e92.	1.7	18
98	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.4	18
99	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	0.6	18
100	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. <i>British Journal of Haematology</i> , 2022, 198, 317-327.	1.2	18
101	Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients. <i>Oncotarget</i> , 2018, 9, 34009-34021.	0.8	17
102	CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100022.	2.0	16
103	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 668-668.	0.6	16
104	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	16
105	Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. <i>Oncotarget</i> , 2016, 7, 74779-74796.	0.8	16
106	Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1963-1971.	1.4	14
107	Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study. <i>Blood</i> , 2019, 134, 695-695.	0.6	14
108	Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial. <i>Blood</i> , 2013, 122, 404-404.	0.6	14

#	ARTICLE	IF	CITATIONS
109	Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells. <i>Experimental Cell Research</i> , 2004, 299, 383-392.	1.2	13
110	Health-care professionalsâ€™ perspective on discussing sexual issues in adult patients after haematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 235-245.	1.3	13
111	Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. <i>Molecular Imaging and Biology</i> , 2018, 20, 1025-1034.	1.3	13
112	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). <i>Blood</i> , 2013, 122, 661-661.	0.6	13
113	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	0.8	13
114	Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. <i>Leukemia Research</i> , 2014, 38, 816-821.	0.4	12
115	Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2020, 105, e80-e83.	1.7	12
116	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1274-1278.	0.5	12
117	Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors. <i>HemaSphere</i> , 2021, 5, e606.	1.2	12
118	Genomic amplification of MYC as double minutes in a patient with APL-like leukemia. <i>Molecular Cytogenetics</i> , 2014, 7, 67.	0.4	11
119	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1840-1849.	3.3	11
120	Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 81, 27-34.	0.4	11
121	Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant. <i>HemaSphere</i> , 2021, 5, e561.	1.2	11
122	Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. <i>Cancers</i> , 2021, 13, 2452.	1.7	11
123	Simplified frailty assessment tools: are we really capturing frailty or something else?. <i>Leukemia</i> , 2020, 34, 1967-1969.	3.3	11
124	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4593.	1.0	11
125	The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma. <i>Blood</i> , 2019, 134, 137-137.	0.6	10
126	Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile. <i>Matrix Biology</i> , 2007, 26, 561-571.	1.5	9

#	ARTICLE	IF	CITATIONS
127	Self-Reported Sexual Function in Sexually Active Male Hodgkin Lymphoma Survivors. <i>Sexual Medicine</i> , 2020, 8, 428-435.	0.9	9
128	Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. <i>Immunotherapy</i> , 2021, 13, 143-154.	1.0	9
129	Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2165-2172.	2.5	9
130	Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate. <i>Blood</i> , 2012, 120, 333-333.	0.6	9
131	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISC). <i>Blood</i> , 2013, 122, 4087-4087.	0.6	9
132	Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network. <i>Blood</i> , 2013, 122, 688-688.	0.6	9
133	Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. <i>Lupus Science and Medicine</i> , 2015, 2, e000121.	1.1	8
134	Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmacoeconomic assessment. <i>European Journal of Haematology</i> , 2020, 105, 635-645.	1.1	8
135	Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells. <i>Cells</i> , 2021, 10, 665.	1.8	8
136	Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 157-157.	0.6	8
137	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2219.	1.7	7
138	Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper. <i>Journal of Geriatric Oncology</i> , 2021, 12, 499-507.	0.5	7
139	Accurate Detection of Residual Leukemic Stem Cells In Remission Bone Marrow Predicts Relapse In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 759-759.	0.6	7
140	Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN. <i>Blood</i> , 2011, 118, 633-633.	0.6	7
141	Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial. <i>Blood</i> , 2016, 128, 1141-1141.	0.6	7
142	Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. <i>Blood</i> , 2020, 136, 8-9.	0.6	6
143	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013, 122, 4067-4067.	0.6	6
144	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISC). <i>Blood</i> , 2013, 122, 4088-4088.	0.6	6

#	ARTICLE	IF	CITATIONS
145	Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMG). <i>Blood</i> , 2014, 124, 170-179.	0.6	6
146	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	0.8	6
147	Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8003-8003.	0.8	6
148	Is There a Need for Extensive Haemostatic Screening in Neurosurgical Patients Using Valproic Acid?. <i>Blood</i> , 2012, 120, 1137-1137.	0.6	6
149	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. <i>Blood Cancer Journal</i> , 2021, 11, 178.	2.8	6
150	Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands. <i>Blood Cancer Journal</i> , 2022, 12, 41.	2.8	6
151	Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015. <i>Blood Advances</i> , 2017, 1, 1839-1841.	2.5	5
152	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. <i>Leukemia and Lymphoma</i> , 2021, 62, 549-559.	0.6	5
153	First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018. <i>Blood Cancer Journal</i> , 2021, 11, 22.	2.8	5
154	Improving the identification of frail elderly newly diagnosed multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 2715-2719.	3.3	5
155	Recommended patient information sheet on the impact of haematopoietic cell transplantation on sexual functioning and sexuality. <i>Ecancermedalscience</i> , 2019, 13, 987.	0.6	5
156	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 5606.	1.7	5
157	Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands. <i>Blood</i> , 2018, 132, 3555-3555.	0.6	4
158	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs).. <i>Blood</i> , 2011, 118, 3839-3839.	0.6	4
159	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2012, 120, 803-803.	0.6	4
160	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016, 128, 3117-3117.	0.6	4
161	Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study. <i>Blood</i> , 2016, 128, 3305-3305.	0.6	4
162	Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8538-8538.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012, 120, 1726-1726.	0.6	4
164	The need for information among patients with hematological malignancies: Psychometric analyses of the 62-item Hematology Information Needs Questionnaire (HINQ-62). <i>PLoS ONE</i> , 2018, 13, e0201699.	1.1	3
165	Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e832-e835.	0.2	3
166	Reply to: "Discussing sexuality in cancer care: towards personalized information for cancer patients and survivors". <i>Supportive Care in Cancer</i> , 2021, 29, 535-537.	1.0	3
167	The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review. <i>Cancer Imaging</i> , 2021, 21, 36.	1.2	3
168	Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.. <i>Blood</i> , 2009, 114, 399-399.	0.6	3
169	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3971-3971.	0.6	3
170	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011, 118, 996-996.	0.6	3
171	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. <i>Blood</i> , 2015, 126, 4080-4080.	0.6	3
172	No Harmful Impact of 90Yttrium-Ibritumomab Tiuxetan Combined with BEAM On Bone Marrow Microenvironment.. <i>Blood</i> , 2009, 114, 3538-3538.	0.6	3
173	An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).. <i>Blood</i> , 2012, 120, 2844-2844.	0.6	3
174	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. <i>Supportive Care in Cancer</i> , 2021, 29, 3783-3792.	1.0	2
175	Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates. <i>Hemato</i> , 2021, 2, 116-130.	0.2	2
176	Deletion 17p: a matter of size and number?. <i>Blood</i> , 2021, 137, 1135-1136.	0.6	2
177	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. <i>Blood</i> , 2019, 134, 704-704.	0.6	2
178	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. <i>Blood</i> , 2019, 134, 4165-4165.	0.6	2
179	In Acute Myeloid Leukemia Both Malignant and Normal Stem Cells Can Be Detected in Remission Bone Marrow.. <i>Blood</i> , 2006, 108, 2537-2537.	0.6	2
180	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). <i>Blood</i> , 2008, 112, 163-163.	0.6	2

#	ARTICLE	IF	CITATIONS
181	First Interim Analysis of HOVON 76: Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma.. Blood, 2009, 114, 2285-2285.	0.6	2
182	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	0.6	2
183	No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study. Blood, 2013, 122, 2132-2132.	0.6	2
184	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study). Blood, 2013, 122, 287-287.	0.6	2
185	Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. Blood, 2013, 122, 3332-3332.	0.6	2
186	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4073-4073.	0.6	2
187	The Relationship of Response on Time to Next Treatment Based on Evidence from Two RCTs in Newly Diagnosed Stem Cell Transplantation Ineligible Multiple Myeloma Patients. Blood, 2016, 128, 2141-2141.	0.6	2
188	The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved. Blood, 2010, 116, 2725-2725.	0.6	2
189	Interferon- β -Induced Upregulation of Immunoproteasome Subunit Assembly Overcomes Bortezomib Resistance of Leukemia Cell Lines Harboring Bortezomib-Induced Mutations in Constitutive PSMB5. Blood, 2012, 120, 1346-1346.	0.6	2
190	Sexual problems in patients with hematological diseases: a systematic literature review. Supportive Care in Cancer, 2022, 30, 4603-4616.	1.0	2
191	Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018. Blood, 2021, 137, 2848-2851.	0.6	1
192	Survival in Primary Myelofibrosis: A Population-based Analysis in the Netherlands. HemaSphere, 2021, 5, e595.	1.2	1
193	Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM). Blood, 2019, 134, 4740-4740.	0.6	1
194	Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome.. Blood, 2006, 108, 2314-2314.	0.6	1
195	Identification of Primitive Subpopulations of Acute Myeloid Leukemia Side Population (SP) Stem Cells Defined by Differentiation Status and Malignant Character.. Blood, 2006, 108, 2538-2538.	0.6	1
196	Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.. Blood, 2007, 110, 3469-3469.	0.6	1
197	High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia. Blood, 2008, 112, 2537-2537.	0.6	1
198	MicroRNA Profiling In Multiple Myeloma. Blood, 2010, 116, 302-302.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis. <i>Blood</i> , 2014, 124, 2042-2042.	0.6	1
200	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed AL Amyloidosis. <i>Blood</i> , 2016, 128, 4628-4628.	0.6	1
201	Personalized versus standard cognitive behavioral therapy for fear of cancer recurrence, depressive symptoms or cancer-related fatigue in cancer survivors: study protocol of a randomized controlled trial (MATCH-study). <i>Trials</i> , 2021, 22, 696.	0.7	1
202	Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 4120-4120.	0.6	1
203	Sensitivity of Pediatric Acute Leukemia Cells to Bortezomib and Epoxyketone-Based Proteasome Inhibitors: Correlations with Proteasome Subunit Expression. <i>Blood</i> , 2011, 118, 1513-1513.	0.6	1
204	The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance. <i>Blood</i> , 2013, 122, 3841-3841.	0.6	1
205	Superior Identification of Prognostic Relevant Copy Number Abnormalities By SNP-Based Genomic Arrays As Compared to Interphase FISH in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4426-4426.	0.6	1
206	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 2207-2207.	0.6	1
207	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
208	Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 624-634.	0.2	0
209	Addition by subtraction. <i>Blood</i> , 2021, 137, 3005-3006.	0.6	0
210	Conditioning Regimens in Stem Cell Transplantations Facilitate Homing by Increasing Bone Marrow SDF-1 through Induction of SDF-1 Gene Transcription.. <i>Blood</i> , 2004, 104, 4958-4958.	0.6	0
211	Biochemical Characterization and Gene Expression Profiling of Cytarabine Treated Stromal Fibroblasts Reveal Regulatory Mechanisms Affecting Hyaluronan and Heparan Sulfate Proteoglycans.. <i>Blood</i> , 2004, 104, 1304-1304.	0.6	0
212	Specific Detection of Aberrant and Normal Stem Cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem Cell Therapy.. <i>Blood</i> , 2008, 112, 1353-1353.	0.6	0
213	Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1790-1790.	0.6	0
214	Combination of CD34/CD38 Immunophenotypes and Side Population (SP) Reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell In Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1582-1582.	0.6	0
215	Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Approach; Impact for Prognostic and Therapeutic Applications. <i>Blood</i> , 2010, 116, 1834-1834.	0.6	0
216	Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,. <i>Blood</i> , 2011, 118, 3658-3658.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Quantitative in-Vivo Monitoring of Bone Formation in Multiple Myeloma Patients Following Treatment with Bortezomib: A Pilot Study. Blood, 2011, 118, 2939-2939.	0.6	0
218	Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide. Blood, 2012, 120, 3973-3973.	0.6	0
219	Cost-Effectiveness of Rituximab As Maintenance Treatment for Relapsed Follicular Lymphoma: Results of a Population Based Study. Blood, 2012, 120, 4277-4277.	0.6	0
220	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	0.6	0
221	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide. Blood, 2014, 124, 5702-5702.	0.6	0
222	Immunologic Recovery Following Consolidation with 90Yttrium Ibritumomab Tiuxetan (Zevalin®)-BEAM and Autologous Stem Cell Transplantation for Transformed B Cell Non-Hodgkin's Lymphoma. Blood, 2014, 124, 5882-5882.	0.6	0
223	Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler. Blood, 2014, 124, 2026-2026.	0.6	0
224	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	0.6	0
225	Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 2967-2967.	0.6	0
226	Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide. Blood, 2015, 126, 4245-4245.	0.6	0
227	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. Blood, 2015, 126, 2984-2984.	0.6	0
228	Marcks Marks Resistance to Proteasome Inhibitors: Exocytosis of Polyubiquitinated Proteins in Bortezomib-Resistant Leukemia Cells. Blood, 2015, 126, 3712-3712.	0.6	0
229	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 5463-5463.	0.6	0
230	Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells. Blood, 2018, 132, 241-241.	0.6	0
231	The Prognostic Power of Gene Expression Profiling with Cytogenetics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS. Blood, 2020, 136, 24-25.	0.6	0